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INTRODUCTION AND LITERATURE REVIEW 
History  
Cystic Fibrosis (CF) is an inherited disease and affects mostly the respiratory and 
digestive system, causing increased viscosity of the secretions in the lungs and the pancreas, thus 
reducing life expectancy (Davis, 2006).  Symptoms of CF have been documented as early as 
3,000 BC (Busch, 1990); however, the entire spectrum of CF was not recognized and well 
documented until the 1930s.  In 1936, a Swiss pediatrician named the illness “celiac syndrome”, 
and defined it as changes in the pancreas and bronchiectasis as observed in children (Fanconi, 
Uehlinger & Knauer, 1936).  The disease was characterized by malabsorption of fat and protein, 
steatorrhea, growth failure, and pulmonary infection.  Then in 1938 an American pathologist, Dr. 
Dorothy Andersen, described the illness in the medical literature as “cystic fibrosis of the 
pancreas”, after performing numerous autopsies on patients with this issue (Anderson, 1938).  It 
was due to her efforts that it was identified as a distinct clinical entity and identified as familial 
in nature.  Prior to this many cases of CF in general pediatrics were misdiagnosed as whooping 
cough, chronic bronchitis, or pneumonia.  When this was identified as a pathologic diagnosis, 
life expectancy was approximately six months.  It was theorized that CF was an autosomal 
recessive disease believed to arise from abnormal mucus plugging of the exocrine ducts and 
death often occurred from lung infection (Davis, 2006).  Studies mainly focused on 
abnormalities in mucus however, later in 1948 it was noted that many of the infants with CF 
presented with heat prostration (excessive sodium and chloride concentration in sweat), which 
offered a convenient diagnostic sweat test that is still used today (Davis, 2006).  In the mid-
1950’s, patients with CF began to assemble into centers for care for physicians to become 




Matthews and colleagues (1964) established three pillars of treatment: nutritional repletion 
(pancreatic enzyme supplements); relief of airway obstruction (postural drainage and clapping); 
and antibiotic therapy of the lung infection (e.g., oral, intravenous).  In the late 1980s, another 
breakthrough occurred which was the identifying of the CF gene (Knowles et al, 1983; Boucher, 
Stuffts, Knowles, Cantley, & Gatzy, 1986; Kerem et al, 1989).  The diagnosis could then be 
made by direct identification of two mutant CF alleles (CFTR, CF transmembrane conductance 
regulator protein) in a cAMP-regulated chloride channel, which lead to more possibilities of gene 
replacement therapies as part of the treatment for CF (Gibson, Burns & Ramsey, 2003).     
Current 
 Substantial advances in basic and clinical research catalyzed therapeutic improvements 
due to earlier diagnosis through screening.  Better treatment and access to health care have 
improved care and treatments of patients with CF.  In America, approximately 30,000 people are 
living with CF as of 2013, with half the population being 18 years or older (Cystic Fibrosis 
Foundation Patient Registry, 2013).  By obtaining a better understanding of the disease and 
through improving treatment options, life expectancy has been increasing continuously over the 
past 20 years.  The prognosis for CF has improved dramatically from about six months to the 
median survival age to now exceeding more than 35 years today (FitzSimmons, 1993; Davis, 
2006; Cystic Fibrosis Foundation Patient Registry, 2013; MacKenzie et al, 2014).  As of this 
time there is still no known cure for CF, but aggressive management and treatment can ease 
these symptoms and reduce complications.  CF requires an intensive, time-consuming treatment 
of various therapies, such as gene therapy, protein modulation, rehydration of airway surface 
and/or mucolytics, anti-inflammatories, and anti-infective agents (Davies, Ebdon & Orchard, 




condition.    
One of the known therapies to assist with cystic fibrosis is the use of aminoglycoside 
(AGs) antibiotics.  Since their introduction in 1944, multiple AG preparations have become 
available, including gentamycin and tobramycin, and are often used when serious Pseudomonas 
aeruginosa infections are treated (Flume et al, 2009; Ruhl, Cable & Martell, 2014).  As CF 
patients are prone to developing infections of the pulmonary and sinonasal systems, AG 
antibiotics have a role in the management of exacerbations, maintenance therapy after 
acquisition of Pseudomonas aeruginosa and its eradication (Prayle & Smyth, 2010; Davies et al, 
2014).  AG antibiotics, mainly tobramycin, are used as regular treatments for some patients with 
CF.  This class of antibiotic has concentration-dependent effects on bacteria (i.e., increased 
killing as concentrations are increased), suggesting there is greater efficacy at higher 
concentrations (McKinnon & Davis, 2004), although the optimum concentration for treatment of 
lung infections in CF has not been established.  AGs may be administered intravenously or by 
inhalation of a nebulized solution.  Both approaches aim to maximize AG delivery to the 
airways, the site of chronic infection, usually dosed according to body weight or surface area, 
and serum levels guide subsequent doses in a course.  Inhaled therapy delivers AGs directly to 
the site of infection whereas intravenous doses achieve lower airway concentrations, but deliver 
the medication to poorly ventilated lung regions (Prayle & Smyth, 2010).  It is reported that the 
use of AG ototoxicity may range between 60 to 85% of the population (Cystic Fibrosis 
Foundation, 2013; Prescott, 2014).  Typically patients with CF will be on a regimen of using 
inhaled tobramycin daily for a cycle of 28 days then it will be discontinued for a cycle of another 
28 days.  When tobramycin is used in this fashion many patients with CF will be utilizing this 




medication intravenously when admitted to the hospital. 
 Tobramycin is a bactericidal antibiotic that may adversely affect renal and 
cochleovestibular systems however; no clear correlation exists between degree of nephrotoxicity 
and ototoxicity (Henley & Schacht, 1988; Sone, Schachern & Paparella, 1998; Mulheran, Degg, 
Burr, Morgan & Stableforth, 2001).  Cochlear toxicity that results in hearing loss usually begins 
in the high-frequencies and is secondary to irreversible destruction of outer hair cells in the organ 
of Corti, predominantly at the basal turn of the cochlea.  The exact mechanism of tobramycin 
ototoxicity remains unknown however, many cellular processes have been implicated, and this 
continues to be an active area of research (Gonzalez-Garrido, Vega, Mercado, Lopez & Soto, 
2015). 
There is a need to consider the benefit of the tobramycin treatment and its potential for 
serious toxicity (Phillips & Bell, 2001; Al-Aloul et al, 2005; Glass, Plant & Spencer, 2005).  
Patients with CF are particularly susceptible to side effects from exposure to usage of tobramycin 
and their ototoxicity, but whether or not the potential risk of hearing loss is associated is 
imperative.  In the CF population, tobramycin has been shown to cause renal, nephrotoxicity and 
ototoxicity (McCracken, 1986; Munckhof, Grayson & Turnidge, 1996; Forge & Schacht, 2000; 
Nakashima, Teranishi, Hibi, & Kobayashi, 2000; Schacht, Talaska & Ryback, 2012; Huth et al, 
2015), particularly when used for long and repeated courses (Sone et al, 1998; Phillips & Bell, 
2001).  It has also been shown that tobramycin ototoxicity is associated with the likelihood to 
occur with larger doses, higher blood levels, or longer duration of therapy (Mulheran et al, 2001; 
Prayle & Smyth, 2010; Ruhl et al, 2014).  Specifically, a recent article estimated that 
approximately 7% of all patients with cystic fibrosis exposed to tobramycin experience some 




range of reported values from 0% to 16% (Mulheran et al, 2001).     
More research have focused on prevalence of sensorineural hearing loss (SNHL) in CF 
pediatric patients and its relationship to antibiotic use, however, research still varies in adults 
with CF.  Clinical assessment of these patients through pure-tone audiometry and brainstem 
evoked response audiometry shows a prevalence of SNHL ranging from 0% to 17% of the CF 
pediatric population (Haddad, Gonzalez, Kurland, Orenstein & Casselbrant, 1994; Ozcelik et al, 
1996; Jorrisen, Boeck & Feenstra, 1998; Mulheran & Degg, 1997; Mulheran et al, 2001; Cheng 
et al, 2009; Piltcher, Teixeira, Oliveira, Scattolin & Piltcher, 2003) and the adult population 
(Kimberley, Brown & Eggermont, 1993; Mulheran et al, 2001; Suryanarayanan, Taylor & Tan, 
2005).  In opposition, studies have found no significant hearing loss in patients with CF, even 
after an average of four repeated courses of tobramycin (Pedersen, Jensen, Osterhammel & 
Osterhammel, 1987; Mulheran et al, 2001; Scheenstra, Heijerman, Zuur, Touw, & Rijntjes, 
2010) or after single courses (Mulheran et al, 2006; Martins, Camargos, Becker, Becker & 
Guimarães, 2010).  It is typically seen and recommended across various publications of the use 
of once-daily dosing to achieve optimal levels for efficacy while reducing the risk of toxicity 
(Soulsby, Bell, Greville & Doecke, 2009; Smyth, 2010).     
  Due to the ototoxic effects of tobramycin it is recommended that ototoxic monitoring be 
performed on patients with CF.  Although assessing hearing acuity in the frequency range from  
.25 to 8 kHz has become routine clinical practice, evaluating hearing sensitivity beyond 8 kHz is 
necessary when monitoring hearing patients with CF that are receiving ototoxic medication(s).  
High-frequency pure-tone audiometry is the most common method for assessing ototoxicity as it 
begins to cause hearing loss at higher frequencies (i.e., 10, 12, 14, 16, 18, and 20 kHz).  It is 




exposure to ototoxicity (Fausti et al, 1999; Fausti et al, 1992).  Therefore, high-frequency pure-
tone audiometry is a useful tool to detect hearing damage at the earliest possible time.  The early 
detection of hearing damage not only warns clinicians to the status of the auditory insult but also 
provides an opportunity for them to balance the therapeutic effects of drugs with the risks of 
permanent hearing loss.  It is recommended that patients receiving ototoxic medication have 
hearing evaluations weekly to monitor the potential ototoxic effects of medication (ASHA, 1994; 
AAA, 2009).  However, as patients with CF receive treatments daily, every other month for 
years it may not be feasible to monitor hearing weekly to determine hearing threshold shift.  
Currently there is no other standard to potentially monitor hearing.  The question then arises as to 
whether or not there is a less time consuming option for the assessment of hearing on individuals 
that may be relatively accurate in predicting and/or detecting early hearing loss.     
Self-assessment tools have been developed to quantify patient’s subjective perceptions of 
their hearing handicap regarding communication difficulties and their subsequent social and 
emotional consequences.  Some of the most common subjective questionnaires used today 
include the original and screening versions of the Hearing Handicap Inventory for Adults 
(HHIA) (Newman, Weinstein, Jacobson & Hug, 1990), and the Hearing Handicap Inventory for 
the Elderly (HHIE) (Newman & Weinstein, 1988), which both provide individual’s subjective 
impressions of their hearing status.  The HHIE (used for adults over 64 years of age) and the 
HHIA (later modified to be used for adults less than 65 years of age) have demonstrated to be 
useful tools to quantify consequences of hearing loss for those with a hearing impairment 
(Newman & Weinstein, 1988; Newman, Weinstein, Jacobson & Hug, 1991).  The HHIA original 
(25 items) and screening (10 items) versions have high internal consistency of its questions, test-




Lima & Ferrari, 2011; Wolters, Johnson & Isaac, 2011).  Such items cover various situations 
where a hearing problem might cause difficulties or embarrassment, as shown in Appendix A, 
with three possible answers to each item (i.e., ‘yes’, ‘sometimes’ and ‘no’).  This tool can be 
worthwhile additions to the audiologists and other professionals’ (e.g., physicians, primary care) 
test battery as information obtained from the responses can help substantiate patient’s hearing 
complaints not readily apparent.  By results of conventional audiometric testing for example, this 
may facilitate decisions regarding candidacy for amplification, assist in a counseling process, 
serve as a guide designing a client-centered rehabilitation program and serve as a criterion 
measure in documenting the effects of rehabilitation efforts, including hearing aid benefit.  It can 
also be used to better identify those that may be in need of a full audiometric evaluation, 
especially where a hearing test cannot be administered in person in other health clinics. 
There’s limited research in using subjective tools by other medical professionals other 
than audiologists for other health conditions that can be at risk of hearing loss, such as adults 
with cystic fibrosis.  Other common medical areas regarding ear related issues include tumors, 
traumatic injuries, autoimmune inner ear disease etc., however whether subjective tools express 
patients’ concerns of any hearing disabilities is rare as these medical areas are addressing more 
severe concerns of first priority.  Such tools can be used in studies and other medical clinics 
where a hearing test cannot be administered in person to detect patients who might display 
possible hearing difficulties. 
The present study aimed to verify the prevalence of SNHL in patients with CF using the 
HHIA and HHIA-S questionnaires, and a comprehensive audiological evaluation to assess its 




1. If there is a difference between the original version (HHIA) and screening version 
(HHIA-S) self-report questionnaires when administered to patients with CF. 
2. Whether the HHIA and/or HHIA-S could be used to detect any hearing perception 
difficulties in adult patients with CF. 
3. If any factors related to aminoglycoside usage affects how patients with CF subjectively 
perceive having any hearing loss or objectively show affected audiological results. 
METHODOLOGY 
Participants 
 47 participants were recruited from Washington University in St. Louis School of 
Medicine’s (WUSM) Center for Advanced Medicine at the Adult Cystic Fibrosis Clinic in the 
Division of Pulmonary and Critical Care Medicine via either a telephone script or flyer approved 
by the Human Research Protection Office (HRPO).  Using a priori power analysis and sample 
size calculation utilizing G-Power 3.1.9.2 (http://mac.  softpedia.com/get/Math-Scientific/G-
Power.shtml) calculated that 94 participants were needed to investigate differences in subjective 
responses to hearing perception and results from the audiological evaluation testing (comparing 
normal to mild hearing loss).  The calculation was completed using a two-tailed test, alpha level 
of 0.05, and power of 0.80.  Due to limited time constraint of this study and lack of awareness in 
patients with CF and varying hearing loss, the number of participants needed couldn’t be 
achieved to have high statistical power.   
Each participant signed an informed consent form approved by HRPO’s Institutional 




approximately one hour or less.  No compensation was provided and testing was only performed 
on a voluntary basis. 
The database used for the current study was de-identified, as to eliminate the possibility 
of participant identification from data included within the database.  In order to qualify for 
entrance of the study, each participant was required to (a) be between the ages of 18 and 55 
years; (b) be medically diagnosed with CF; (c) have not had any surgical procedures to their ears; 
(d) be cleared via ear otoscopic examination bilaterally as to not have any potential causes of 
sound blockage.  Two participants were dropped from the study; one because he/she did not fit 
the inclusion criteria (i.e., history of ear surgery), and the other did not complete the second half 
of the study (i.e., audiological examination).  Therefore, 45 participants were included for data 
analysis. 
This study required one visitation at the Vision and Hearing Center located at the Center 
for Advanced Medicine where the Primary Investigator (PI) and the PI’s advisor evaluated 
participants.  Participants were seated in a double-walled sound-treated booth.  The audiology 
equipment is calibrated annually following American National Standards Institute (ANSI, 
2004b) and quarterly by the audiology faculty.  A case history was taken to collect demographic 
information.  Example responses included any usage of tobramycin AG antibiotics via 
intravenous (IV) therapy and/or inhaler, duration of use of the medication and other factors 
related to ear problems (i.e., tinnitus, pressure, otalgia, dizziness, family history of hearing loss, 
and noise exposure).  Otoscopy was completed to ensure the ear canals were clear bilaterally.     
HHIA & HHIA-S 
 The HHIA is a 25-item, self-assessment scale composed of 13-item emotional and 12-




HHIA-S contains 10 items, five emotional and five social/situational, selected from the 25-item 
version of the HHIA.  The items comprising the HHIA-S are denoted with an asterisk (*), as 
seen in Appendix A.  Example items exhibiting as emotional scenarios include, Does a hearing 
problem cause you to feel embarrassed when meeting new people? and Do you feel handicapped 
by a hearing problem?  Example items exhibiting as social/situational scenarios include, Does a 
hearing problem cause you difficulty in the movies or theater? and Does a hearing problem 
cause you difficulty when in a restaurant with relatives or friends?  For both scales, a “yes” 
response to an item was given four points, “sometimes” of two points, and “no” response of zero 
points.  Scores for the total HHIA range from 0 to 100, with categorical ranges of 0 to 20 having 
no handicap, 22 to 60 having mild to moderate handicap, and 62 to 100 having severe handicap.  
Scores for the total HHIA-S range from 0 to 40, with categorical ranges of 0 to 8 having no 
handicap, 10 to 24 having mild to moderate handicap, and 26 to 40 having severe handicap.  
Higher score values indicate greater perceived handicap in hearing.  HHIA-S scores were 
determined by extracting responses of the appropriate 10 items from the longer version.  Both 
questionnaires evaluated the total scores, and subtotal scores representing only emotional items 
and only social/situational items.  If the total scores fall in the handicap range (i.e., Mild to 
Moderate Handicap, or Severe Handicap) of severities of subjectively perceiving hearing loss, 
this could be a possible indication that the patient should be referred for an audiological 
evaluation, however no studies used specific cut-offs for patient medical referral. 
 All participants received in-person administration of the HHIA before the audiologic 
evaluation, allowing privacy to complete each item.  Each participant responded to each item, 





 Prior to testing, each participant underwent otoscopic examination with a standard 
otoscope utilized to view each ear canal and tympanic membrane (eardrum).  Any abnormalities 
that could potentially affect test results or prevent sound passing through the ear(s), such as 
cerumen and/or debris impaction, absent or abnormal visual of the eardrum, or other obstructions 
were not further tested and excluded from the study.     
A comprehensive audiologic evaluation was performed on each participant in a sound-
treated booth using the protocols from the Adult Division of Audiology clinic using the Grason 
Stadler GSI-61 audiometer (ANSI, 2004a).  Conventional pure-tone air-conduction (pulsed 
tones) was measured per ear using TDH-50P Telephonic supra-aural headphones at octave and 
mid-octave interval frequencies (i.e., .25, .5, 1, 2, 3, 4, 5, and 8 kHz) to determine the 
participant’s thresholds (softest hearing level).  Pure-tone bone-conduction (pulsed tones) was 
measured per ear using a bone oscillator at each standard and octave frequency (i.e., .25, .5, 1, 2, 
3, and 4 kHz) to determine the participant’s thresholds.  If there was a significant difference 
between right and left ear thresholds (≥40 dB HL) at the same frequency, a masking procedure 
took place to separate the two ears, acoustically, using narrow band noise (NBN) to determine 
accurate thresholds.  Thresholds for pure-tone air-conduction and bone-conduction of 15 dB HL 
or less indicated normal hearing, 16 to 25 dB HL indicated sight hearing loss, 26 to 40 dB HL 
indicated mild hearing loss, 41 to 55 dB HL indicated moderate hearing loss, 56 to 70 dB HL 
indicated moderately-severe hearing loss, 71 to 90 dB HL indicated severe hearing loss, and 91 
dB HL and above indicated profound hearing loss.  To determine type of hearing loss, an air-
bone gap (ABG) difference of more than 10 dB HL indicated a conductive hearing loss, an ABG 
difference of less than or equal to 10 dB HL indicated a sensorineural hearing loss, and a 




Speech recognition thresholds (SRTs) were determined at the softest level of intensity 
(dB HL) using monitored live voice (MLV) (with voice peaking at 0 dB on the VU meter) at 
which familiar two-syllable spondee words (e.g., “baseball”, “toothbrush”, “railroad”) may be 
heard and repeated by the participant per ear.  SRTs that are within ±6 dB HL of pure-tone 
average (PTA) air-conduction thresholds are considered to be in an agreement of each other, 
with an addition indicator that speech thresholds of 15 dB HL or less to be considered normal 
speech understanding.  Word recognition (WRS) percentage scores were determined by the 
correct number of one-syllable words from the NU-6 word lists (e.g., “boat”, “home”, “knock”) 
using a recording of a female speaker.  This was presented at comfortable listening levels of 40+ 
dB Sensation Level (SL) (louder) in reference to their SRT score per ear.  Participants repeated 
25 word-lists if two or less words were incorrectly produced, otherwise repeated the full 50 
word-list.  WRS scores ranging from 90% to 100% indicated normal word recognition, 76% to 
88% indicated slight difficulty, 60% to 74% indicated moderate difficulty, 50% to 58% indicated 
poor recognition, and scores less than 50% indicated very poor recognition.    
Ultra high-frequency evaluation was administered per ear using the high-frequency 
Madsen Itera II audiometer inside the booth with Senheiser HAD 200 supra-aural headphones.    
This was tested using high-frequency octaves (i.e., 9, 10, 11.2, 12.5, 14, and 16 kHz) to find the 
participant’s softest hearing level.  Thresholds ≤15 dB HL for each high-frequency measurement 
was considered normal hearing.   
Immittance audiometry was administered outside of the audiometric test booth using the 
GSI Tympstar (immittance machine).  Tympanometry procedure recorded compliance and 
middle ear pressure per ear for each participant using a 226 Hz tone via probe.  Normal 




peak pressure to range ±100 daPA, and static admittance to be from 0.3 to 1.5 mmhos.    
Acoustic reflex thresholds were recorded for middle ear reflex muscle retractions at high-
intensity stimuli per ear, measuring ipsilateral and contralateral responses at different frequencies 
(i.e., .5, 1, 2, and 4 kHz).  Normal (present) results indicated acoustic reflex thresholds to range 
between 70 to 100 dB HL with repeatable compliance change of 0.02 ml or greater.  If acoustic 
reflex thresholds are present and at adequate intensity levels (i.e., ≤100 dB HL), acoustic reflex 
decay was performed to measure the decline of muscle contraction at 10+ dB SL in reference to 
their previous acoustic reflex threshold (tested only at .5 and 1 kHz, if applicable).  Normal 
acoustic reflex decay needed to remain steady for 10 seconds, revealing present amplitude.   
Statistical Analysis 
 Correlational studies were completed to allow for analysis of relationships between each 
of the variables of interest.  Using the software program R (R Core Team, 2015; Revelle, 2015), 
bivariate correlational analyses were completed for demographic characteristics, self-report 
questionnaire items, and audiometric evaluation results.  Pearson correlational coefficients were 
calculated for each set of variables and significance was determined at the p <0.05 levels, as 
specified by asterisks in the Tables used for this study.  Tables were compiled using the stargazer 
package (Hlavac, 2015) and graphs were compiled using tidry (Wickham, 2016) and ggplot2 
packages (Wickham & Chang, 2015). 
RESULTS 
General Characteristics 
   Participants 
Data from all 45 qualified participants was analyzed to determine the validity of the 




The CF participants ranged from 18 to 51 years, with the average age at 31.2 (SD = 8.2) years.    
Forty percent were female, with a mean age of 30.4 (SD = 8.87) years and sixty percent were 
male, with a mean age of 31.7 (SD = 8.04) years.  There is no significant difference (p > .05) 
between men (N = 27) and women (N = 18) in pure-tone audiometry results, as well as no 
significant difference (p > .05) between right and left ears across conventional and high-
frequency pure-tone testing.  Those who have reported tinnitus (N = 21) compared to those who 
did not report having tinnitus (N = 24) were compared and they are not significant (p > .05).    
   HHIA and HHIA-S 
The HHIA and HHIA-S were examined to find a relationship between the two self-report 
scales and were very highly correlated (r > .85), giving identical results.  The relationship of total 
scores and subscales (i.e., Emotional vs. Social/Situational) from the questionnaires were 
examined and the average correlation was 0.92 and the smallest correlation was 0.82.   
Therefore, the two scales are nearly identical and will focus on using the longer questionnaire 
(i.e., HHIA) for better estimates of self-report perception of hearing loss for the remaining of this 
study.    
   Audiological Evaluation 
In Figure 1, hearing thresholds (dB HL) for all participants are represented on an 
audiogram-like representation across conventional frequencies (i.e., .25 to 8 kHz) for right and 
left ear.  Average hearing thresholds, the red line as demonstrated from Figure 1, are displayed 
for each ear.  Average hearing thresholds for the right ear are as followed: 15 dB HL at .25 kHz; 
13 dB HL at .5 kHz; 9 dB HL at 1 kHz; 9 dB HL at 2 kHz; 11 dB HL at 3 kHz; 10 dB HL at 4 




followed: 11 dB HL at .25 kHz; 10 dB HL at .5 kHz; 8 dB HL at 1 kHz; 6 dB HL at 2 kHz; 12 
dB HL at 3 kHz; 13 dB HL at 4 kHz; 16 dB HL at 6 kHz; 19 dB HL at 8 kHz. 
In Figure 2, hearing thresholds for all participants are represented on an audiogram-like 
representation across ultra high-frequencies (i.e., 9 to 16 kHz) for right and left ear.  Average 
hearing thresholds, the red line as demonstrated from Figure 2, are displayed for each ear.  
Average hearing thresholds for the right ear are as followed: 19 dB HL at 9 kHz; 19 dB HL at 10 
kHz; 21 dB HL at 11.2 kHz; 18 dB HL at 12.5 kHz; 23 dB HL at 14 kHz; 23 dB HL at 6 kHz.  
Average hearing threshold for the left ear are as followed: 22 dB HL at 9 kHz; 22 dB HL at 10 
kHz; 25 dB HL at 11.2 kHz; 26 dB HL at 12.5 kHz; 25 dB HL at 14 kHz; 20 dB HL at 16 kHz. 
 The comparison of all participants was examined against baseline levels of normal 
hearing threshold (≤15 dB HL) and is shown in Table 1.  This sample showed significantly 
poorer hearing on several of the high-frequency variables in the left ear (i.e., 9, 10, 11.2, 12.5, 
and 14 kHz) and right ear (i.e., 11, 14, and 16 kHz). 
HHIA Scores and Audiological Evaluation 
 Correlations were examined between the HHIA total and subtotal scores (i.e., Emotional 
and Social/Situational) and results of the air-conduction and bone-conduction conventional 
audiometry.  Values that are statistically significant (p < .05, greater than r = .4) are shown in 
Table 2.  Air-conduction frequencies are significant (p < .05, greater than r = .4) for total and 
subtotal HHIA scores for both ears at .25 and .5 kHz and for pure-tone average.  In the right ear, 
there’s significance (r = .4) across all HHIA scores at 1, 4, 6, and 8 kHz, and in the left ear, 
there’s significance across all HHIA scores at 2 kHz.  Only bone-conduction at .25, .5 and 4 kHz 
right ear only show significance across all HHIA scores.  The rest of the conventional 




3 and 4 show graphical correlations between the relationships of the HHIA scores and 
conventional audiometry results (i.e., pure-tone air-conduction and bone-conduction), showing a 
stronger correlation.     
Correlations were examined between the HHIA total and subtotal scores (i.e., Emotional 
and Social/Situational) and results of ultra high-frequency audiometry as shown in Table 3.  As 
all correlations were approximately .2 or .3, it is not statistically significant (greater than r = .4) 
across all frequencies.  Figure 5 shows small correlations, again, not statistically significant.    
There were no significant correlations between the HHIA questionnaire and speech 
audiometry (i.e., SRT and WRS), as well as immittance audiometry (i.e., tympanometry, ART 
and reflex decay), therefore will not be discussed regarding statistical analyses for the remainder 
of the study.    
 Of the 45 participants, a comparison was made between the self-report response scores 
(i.e., Normal Handicap, Mild to Moderate Handicap, and Severe Handicap) to the objective 
audiological results of the hearing test (i.e., normal hearing vs. abnormal hearing).  For example 
in Table 4, you’ll see pure-tone averages of the right (Table 4A) and left (Table 4B) ears were 
compared to self-report responses.  Very few participants (i.e., Table 4A Right Ear: N = 3 report 
Mild to Moderate Handicap; N = 1 report Severe Handicap; Table 4B Left Ear: N = 1 report 
Mild to Moderate Handicap; N = 1 report Severe Handicap) experience abnormal hearing, as 
measured both objectively and subjectively.  This sample size is too small to compare 
differences between objectively hearing impaired participants and normal hearing participants.  
However, there seems to be a number of participants with normal hearing (Table 4A Right Ear: 
N = 35; Table 4B Left Ear: N = 37) who report perceiving of having a mild hearing impairment 




Of all participants, only 39 reported Mild to Moderate Handicap or Severe Handicap on 
the HHIA (defined as 22+ points).  Only 1 participant reported Severe Handicap (defined as 62+ 
points) so they cannot be assessed separately.  Therefore, those reported Mild to Moderate 
Handicap or Severe Handicap is compared to the baseline of Normal hearing (≤15 dB HL), as 
shown in Table 5.  Despite reporting hearing loss, participants only demonstrated significance (p 
< 0.5) objectively at two of the ultra high-frequencies (i.e., left ear at 11 and 12 kHz) and no 
significance (p > 0.5) at conventional frequencies. 
Aminoglycoside - Tobramycin, HHIA Scores, and Audiological Evaluation 
The relationship between the age of CF diagnosis and the age onset of receiving 
tobramycin treatment is compared to self-report questionnaire responses, and conventional and 
ultra high-frequency pure-tone audiometry tests, as shown in Table 6.  There are significant 
correlations (greater than r = .4; p < .05) between the age of CF diagnosis and the age receiving 
tobramycin treatment with results of ultra high-frequency audiometry testing.  Participants who 
were diagnosed at a later age showed affected ultra high-frequency audiometry (r = .52, p < .05).  
Increase in age at diagnosis is also correlated with increase in age of tobramycin treatment 
received (r = .56, p < .05); however there is some variability in how much later after CF 
diagnosis that treatment of tobramycin began. 
At the time of the study, all participants were asked if he or her were currently taking any 
tobramycin medication or not, whether it was via inhale or IV therapy.  As there was only one 
affected frequency (i.e., air-conduction at 2 kHz in right ear) correlated between the status of 
intake at time of test with the self-report responses and audiometric pure-tone testing, this data 
was not enough to show any significance in this relationship.   




Between type of intake of tobramycin, 16 participants have only used inhaled, 1 
participant only used IV therapy and 26 participants have used both.  Because only one 
participant used IV therapy only, this cannot be comparable to inhaled participants only or those 
that use both.  Shown in Table 7, participants who inhale tobramycin (N = 0) were compared to 
participants who do not (N = 45), and shown in Table 8, those who use IV therapy (N = 27) to all 
participants who do not (N = 18).  None of the tests are significant (p > .05) in regards to the 
comparisons of participants inhaling to those not, and participants who use IV therapy to those 
do not.   
An independent sample t-test was used to compare ages of participants using inhalation 
to those not using inhalation.  There is no difference in age between patients who inhaled (M = 
31.19, SD = 8.44) and those who did not (M = 30.67, SD = 7.51; t(43) = -0.1, p = 0.92).  An 
independent sample t-test was used to compare ages of patients using IV therapy to those not 
using an IV.  There is no difference in age between participants who use IV therapy (M = 31.11, 
SD = 7.81) and those who did not (M = 31.22, SD = 9.23; t(43) = 0.04, p = 0.97).  An 
independent sample t-test was used to compare the ages of participants using tobramycin at the 
time of testing and those not using tobramycin.  There is no difference in age between 
participants who were using tobramycin at the time of testing (M = 31.17, SD = 77.63) and those 
who did not (M = 31.14, SD = 9.14; t(43) = -0.01, p = 0.99).       
Duration of Tobramycin 
 Two groups were separated in the duration of using tobramycin, Group 1 consisting of 25 
participants (56%) using tobramycin 10 years or less, and Group 2 consisting of 20 participants 
(44%) using tobramycin more than 10 years.  Table 9 shows the means and SD of each group on 




difference (p = .05).  Only one of the tests is significant (p < .05), which was 250 Hz in the right 
ear.  However, in general, there is no correlation between duration of tobramycin and 
conventional audiometry testing.  Yet, it is observed that participants with CF who had been 
taking tobramycin for 10 years or fewer scored lower (M = 4.2, SD = 6.56) on the self-report 
questionnaire than participants with CF who had been taking tobramycin for more than 10 years 
(M = 14.5, SD = 23.78; t(43) = -2.07, p < .  05). 
The comparison of participants using tobramycin for 10 years or fewer were examined 
against baseline levels of normal hearing threshold (≤ 15 dB HL) and is shown in Table 10.    
This sample showed significantly worse hearing on a few high-frequency variables in the right 
ear (i.e., 14 and 16 kHz) and left ear (i.e., 14 Hz).  In Table 11, it’s showing the comparison of 
participants using tobramycin for more than 10 years compared to baseline normal hearing 
threshold (≤ 15 dB HL).  This sample showed significant worse hearing on several of the high-
frequency variables in the right ear (i.e., 9 and 11 kHz) and in the left ear (i.e., 8, 9, 10, 11, and 
12 kHz).   Figure 6 graphically represents the average hearing thresholds (dB HL) across 
conventional and ultra high-frequencies, differentiating the duration of tobramycin medication 
intake in participants with CF (10 years or fewer compared to more than 10 years).  Again, there 
is no correlation however those using tobramycin more than 10 years shows poorer hearing 
thresholds on the graph than those using tobramycin for 10 years or fewer. 
DISCUSSION 
 Recent studies have shown patients with CF to be at high risk for SNHL (Cheng et al, 
2009; Mulheran et al, 2001; Tarshish et al, 2016), however others have not (Mulheran et al, 
2006; Scheenstra et al, 2010).  In this study of patients with CF, there is no validity in hearing 




hearing loss.  Even though the original (HHIA) and screening (HHIA-S) questionnaires can 
either be administered as they reveal similar outcomes and high correlations, this self-report may 
not be an efficient tool to detect hearing perception difficulties in adults with CF. 
HHIA Scores and Audiological Evaluation 
Positive values at frequencies listed in Table 2 indicate that as a patient self-reports 
greater hearing loss (i.e., Mild to Moderate, and Severe Handicap), the results of the objective 
hearing test indicated greater hearing loss.  However, many non-significant correlations are still 
substantially large.  With the limited number of participants, there is not enough correlation in 
the relationship between the self-reports of hearing loss and the objective tests across frequencies 
and there are discrepancies in the interpretation.  For example, of the participants who self-report 
normal hearing (HHIA score ranging from 0 – 20), most do have normal hearing.  However, of 
the participants who report Mild to Moderate Hearing Handicap (HHIA score ranging from 22 – 
60), objectively normal hearing in conventional audiometry is found.  Clinically, this can lead to 
difficulty with decision-making regarding referrals from a medical professional, due to lack of 
consistency.  Overall, this suggests that even though there is a strong relationship between self-
reported hearing loss and objective measures of hearing loss, not all patients show consistency.  
Therefore, some patients who are suffering from hearing loss are subjectively experiencing 
hearing loss; however some patients report hearing loss when they actually have normal hearing.    
Even though there weren’t enough participants with CF showing various objective 
hearing loss results, it was anticipated that ultra high-frequency thresholds would be affected 
more, as there is potential side effects of tobramycin and its ototoxicity at pitches above 8000 Hz 
(Fausti et al, 1999; Fausti et al, 1992). There was no statistical significance between the HHIA 




report questionnaire would not be a good tool to detect a patient’s hearing loss in this population 
at those measured frequencies (i.e., >8 kHz).  However it should be noted that common speech 
sounds, used in daily communication, are produced more at conventional frequencies (i.e., 
between .25 and 8 kHz), which is why those frequencies are commonly tested for a conventional 
audiological evaluation (Jongman, Wayland & Wong, 2000; Pittman, Stelmachowicz, Lewis, & 
Hoover, 2003).  Decrease in hearing thresholds at conventional frequencies may cause patients to 
realize difficulty with missing speech or have trouble hearing in a variety of listening 
environments.  Even if patients demonstrated hearing loss at higher frequencies but normal 
hearing at conventional frequencies, hearing difficulty might not be noticeable to the patient 
regardless.  Therefore, the HHIA would not be useful in medical clinics that assist patients with 
risks of ototoxicity, as it may not detect changes in hearing at ultra high-frequencies.  It may be 
useful in detecting hearing loss at more conventional speech frequencies, however if ototoxicity 
is the cause of the hearing loss, irreparable damage may already have occurred to the ultra high-
frequency region of the cochlea resulting in permanent hearing loss and tinnitus.   
As seen in Table 5, again, there is no correlation with self-reported hearing loss and pure-
tone testing when comparing Mild to Moderate Handicap and Severe Handicap to Normal 
hearing on the self-report questionnaire.  Using the cutoffs (i.e., ≤15 dB HL for conventional and 
ultra high-frequencies), the HHIA does not adequately assess hearing loss.  Different 
audiological clinics may use various cutoffs of what is considered normal hearing in the adult 
population or during ototoxic monitoring, ranging from 15 – 25 dB HL whether in conventional 
and/or higher frequency testing.  It should also be noted that during ototoxic monitoring, there is 




(Konrad-Martin et al, 2005), which is why there may be a lack in standard norms of cutoffs in 
those higher regions of audiometry testing.   
 As there was a lack of CF participants that demonstrated abnormal hearing, sufficient 
data was not available to demonstrate any correlations with speech audiometry testing (i.e., SRT 
and WRS) or immittance testing (i.e., tympanometry, ART).  These two tests are typically 
performed at baseline testing, however subsequent testing may not be performed for ototoxic 
monitoring unless a significant change occurs in hearing threshold (AAA, 2009; Campbell & 
Durrant, 1993; Campbell, 2004).  Even though some patients might report little to no hearing 
difficulties, it does not appear that any of these individuals meet threshold for objective hearing 
loss, therefore speech audiometry and immittance tests do not capture true hearing loss in the CF 
population. 
Aminoglycoside - Tobramycin, HHIA Scores, and Audiological Evaluation 
From Table 6, correlations with the age that participants with CF have been diagnosed 
and when they received treatment, in relationship with pure-tone testing are demonstrated.  As 
patients with CF were diagnosed later in age as well as when they received treatment, it seems as 
though regions at higher frequencies (>8 kHz) are more affected (poorer hearing) than 
conventional frequencies (≤ 8 kHz) (better hearing). This supports various research studies as to 
the importance in monitoring ultra high-frequency thresholds in populations who undergo 
treatment with tobramycin (Mulheran et al, 2001; Schacht et al, 2012; Huth et al, 2015; Fausti et 
al, 1999; Fausti et al, 1992).  There should be some consideration in frequent ototoxic monitoring 
if a patient with CF is later diagnosed and treated than earlier, but whether or not there’s an age 




 No difference was noted whether or not participants with CF were currently being 
medicated with tobramycin or not at the time of testing.  Therefore, this area may be more useful 
in a longitudinal study that examines repeatable audiological testing (e.g., monthly following 28 
day cycles) and whether or not actively using tobramycin is correlated with hearing thresholds in 
pure-tone testing. 
Type of Tobramycin Intake 
There are no significant correlations with the type of tobramycin usage (i.e., inhale, IV 
therapy) or age of the CF participants in comparison to their audiological evaluation.  This is 
most likely due to the small sample size and limited number of participants that demonstrated 
hearing loss.  In relation, other literature has found no differences in type of tobramycin therapy 
that was associated with detectable renal toxicity or ototoxicity in this population (Wagener et al, 
2013; Hennig et al, 2014).  Therefore, further research should investigate this area in a larger 
sample population and include groups who objectively have hearing impairment. 
Duration of Tobramycin   
Inhalation of tobramycin for 10 years and fewer or greater than 10 years, did not affect 
the audiological tests at conventional frequencies.  Even though there is statistical significance at 
one frequency, it is not enough data to support a relationship.  However, it is interesting to note 
that patients with CF who had been taking tobramycin for greater than 10 years have higher 
threshold averages in conventional air-conduction pure-tones (poorer hearing) than patients who 
had been taking tobramycin for 10 years or less (as shown in Figure 6).  This relationship 
demonstrates that there might be some association in whether or not patients with CF need to be 
referred for audiological test(s) depending on duration of ototoxic medications, however there is 




The comparison of participants using tobramycin for 10 years or less were examined 
against baseline levels of normal hearing threshold (≤ 15 dB HL) and is shown in Table 10.  This 
sample demonstrated significantly worse hearing on a few high-frequency variables in the right 
ear (i.e., 14 and 16 kHz) and left ear (i.e., 14 Hz).  A comparison of participants using 
tobramycin for greater than 10 years compared to baseline normal hearing threshold (≤ 15 dB 
HL) is shown in Table 11.  This sample demonstrated significant worse hearing on several of the 
ultra high-frequency variables in the right ear (i.e., 9 and 11 kHz) and in the left ear (i.e., 8, 9, 10, 
11, and 12 kHz).  It should be noted that patients with CF who use tobramycin for greater than 
10 years have shown to have more frequencies affected, specifically at ultra high-frequencies, 
than those who use tobramycin for 10 years or fewer.  However, this data is not similar across 
ears, with the exception at 14 kHz, for those using tobramycin 10 years or less, and at 9 and 11 
kHz for those using tobramycin greater than 10 years.  Insufficient affected frequencies were 
obtained to prove that the duration of tobramycin intake could potentially be associated to 
harming ultra high-frequency regions.  However, with more data a clearer picture could be 
obtained.  McRorie, Bosso, and Randolph’s study (1989) examined patients with CF who were 
treated with AGs for more than 20 years compared to those treated less than 20 years and found 
elevated thresholds in all frequencies tested in (elevations only in frequencies higher than 16 
kHz).  This may support the consideration that duration of treatment may have an impact on 
potential risks of hearing loss. 
AAA and ASHA (AAA, 2009; ASHA, 1994) recommend weekly audiological 
evaluations for patients receiving ototoxic medications regardless of duration of use, however, 
for the CF population receiving ototoxic medication this recommendation would not be feasible.  




using this medication for years at a time.  Having an audiological evaluation every week would 
become overly time consuming and increase the already high medical costs for the population.  
More data is needed to determine the best course of treatment for this population.  When more 
information is gathered a testing schedule could be implemented to assure that hearing loss is 
monitored without causing difficulty for the patient financially as well as follow up 
appointments.   
The duration of use of and dosage of tobramycin could be of some importance of whether 
or not a patient with CF should have an audiological referral, however, there is no sufficient data 
to determine these questions.  Various studies have shown a prevalence of SNHL in the CF 
population (Mulheran et al, 2001; Cheng et al, 2009; Piltcher et al, 2003) however even with 
repeated courses of tobramycin, others have found no significant hearing loss (Mulheran et al, 
2001; Scheenstra et al, 2010).  Until this could be established more fully it would be 
recommended that patients receiving tobramycin whether inhaled or IV should have an annual 
audiological evaluation.  An audiological evaluation should be performed more often if the 
patient notes any change in hearing, tinnitus, fullness in the ear, otalgia or dizziness. 
Through this it may be determined at what duration of use in years, is potentially 
considered a significant difference that would be significant and may guide the physicians or 
audiologists to recommend audiological evaluations more often.  Determining when testing may 
become more appropriate may be beneficial as the life expectancy of patients with CF increases.  
As life expectancy increases the use of tobramycin will increase and the likelihood of ototoxicity 
would increase.  Therefore an appropriate protocol for patient receiving ototoxic medications 





 There are several limitations to this study that need to be addressed.  A lack of 
documentation in the medical database system and in patient knowledge regarding certain 
demographic related questions was noted.  For example, patients with CF estimated the age they 
were diagnosed, when they began tobramycin treatment, and/or the amount of antibiotic 
medication they received.  Many patients with CF had difficulty remembering their treatment 
cycle(s) or duration of treatment.  In addition to inaccurate subjective in-person responses, 
patient chart information in the database was not clear, as the reports would not specify the 
dosage of tobramycin.  This was especially the case regarding the use of IV tobramycin as 
typically this is provided in the hospital and many patients could not accurately determine the 
number of times he or she was admitted to the hospital.  Hospital records were also inaccessible, 
as documentation was maintained by other medical clinics.  These variables were considered to 
be important and should be concise and accurate across patient history. 
Although self-report questionnaires can be a popular methodology in behavioral studies 
because of their utility (less time consuming and efficient), there can be many problems with 
assessing them.  The HHIA item scores (i.e., Total, Emotional, Social/Situational) may have 
been affected by the individual’s responses from lack of introspective ability (honesty and 
accuracy), interpretation differences of items, limited rating of scale, response bias, and state of 
health at time of assessment (e.g., personality, concentration, attitude etc.).  These difficulties 
should be noted and in need to be countered through a careful design and application of self-
report measures. 
More importantly, there was a lack of participants with CF in this study due to the time 
constraint of the recruitment period and testing timeframes, lack of motivational factors of 




was already a low statistical power, this negatively affected the likelihood that a nominally 
statistically significant finding may truly reflect the effect.  Specifically, there was a lack of 
patients with CF who demonstrated having objective hearing impairment (i.e., poorer than mild 
hearing loss, ranging from moderate to profound).  Most of the participants had normal hearing 
results, regardless of the various demographic variables or self-report responses analyzed and 
discussed.  Insufficient participants with various types of hearing impairment were obtained that 
would show any potential correlations discussed in this study. 
During patient recruitment, it is possible that some patients with CF volunteered due to 
his or her perceived hearing loss.  While others may have not volunteered due to a lack of 
perceived hearing loss.  Therefore, some patients with hearing loss may not have been evaluated 
and could have provided additional value to the research. 
Further Research 
 Future research should examine the duration of tobramycin usage in the CF population to 
further investigate the potential risk correlations to hearing loss.  In addition to this, type of 
tobramycin intake (i.e., inhalation, IV therapy) should be taken into consideration with a larger 
sample size to determine, if any, differences in treatment.  It would be interesting to see a 
different direction in research in regards to type and/or duration of treatment methods and 
ototoxicity monitoring outside of weekly standard guidelines taken from ASHA and AAA.  For 
example, weekly monitoring compared to monthly or annually ototoxic monitoring and its 
possible association to hearing loss.  This could notify and aware other medical professionals 
about additional factors that could assist in better medical referrals. 
Improved recruitment procedures could be implemented to recruit participants with CF 




to notice differences between tobramycin characteristics, such as intake type and duration in use, 
and testing at conventional and at ultra high-frequency pure-tone thresholds.  Recruiting a larger 
sample size will also benefit results as mentioned and to have a higher statistical power. 
A longitudinal study could be useful in the methodology used in this present study to 
show any changes in tobramycin intake and audiological evaluation thresholds, specifically at 
ultra high-frequency thresholds over time.  This could also assist with the referral base of other 
medical professionals in regard the duration of use of ototoxicity and when a patient with CF 
may be at risk of hearing loss. 
CONCLUSION 
 Adult patients with CF may be at high risk for developing SNHL due to frequent 
exposure to AGs.  From this present study, self-report questionnaire(s) may not be a valuable 
tool to detect potential hearing loss, especially at unnoticed ultra high-frequency regions of 
hearing.  Therefore further investigation is warranted to determine a protocol that is efficient and 
that is cost effective.  This should be appropriately available to other medical professionals to 
administer to patients with CF in a timely manner (as well as to other health conditions at risk of 
hearing loss).  As life expectancy in the CF population continues to increase, there may be more 
exposure to tobramycin intake; hence patients are at higher risk of developing bilateral SNHL, 
potentially impacting his or her quality of life.  Since SNHL has been shown to have a significant 
impact on social and emotional development, it is recommended that an increased awareness of 
the possibility of hearing loss in patients with CF among clinicians, patients and families with 
anticipatory planning regarding habilitation of HL should it occur.  The CF population should 
have routine and longitudinal audiometric evaluations as part of their overall management, 




type of tobramycin intake etc.) to delineate the optimal treatment without causing potential risk 
of hearing loss.  The addition of SNHL to the already extensive set of health challenges that 
patients with CF face creates a need for intensified identification, prevention, and education, 
potentially through changes to the CF care guidelines, which currently varies in recommend 
routine audiometric screening.  The incidence of hearing loss in the CF population requires 
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Correlation is significant at the 0.05 level (2-tailed) 
 
Table 1: Correlation of all participants to baseline hearing threshold of ≤15 dB HL as shown 
above.  Labeled with an asterisk above, there is significant (p < .05) ultra high-frequency 



















 *. Correlation is significant at the 0.05 level and greater than r = .4 (2-tailed) 
 
Table 2: Correlations between HHIA questionnaires subtotal and total scores and results of 
conventional audiometry tests (air- and bone-conduction).  Columns ending in “E” indicate E 
subtotals (emotional), in “S” indicates S subtotals (social/situational), and the HHIA indicates 
total score.  Values with an asterisk indicate that these correlations are statistically significant (α 












 *. Correlation is significant at the 0.05 level (2-tailed) 
 
Table 3: Correlations between HHIA questionnaire subtotal and total score and results of ultra 
high-frequency audiometry.  Columns ending in “E” indicate E subtotals (emotional), in “S” 
indicates S subtotals (social/situational), and the HHIA indicates total score.  No correlations are 





























4A: Right Ear 
 
  
4B: Left Ear 
 
  
Table 4: Comparison of HHIA self-report perception of hearing with pure-tone average hearing 





























 *. Correlation is significant at the 0.05 level (2-tailed) 
 
Table 5: Comparison of self-reported impairment (i.e., Mild to Moderate Handicap, Severe 










 *. Correlation is significant at the 0.05 level and greater than r = .4 (2-tailed) 
 
Table 6: Correlation between age of participant diagnosed with CF and age of participant that 
received treatment, in comparison to the self-report questionnaire, conventional and ultra high-









 *. Correlation is significant at the 0.05 level (2-tailed) 
 
Table 7: Comparison of inhalation and non-inhalation participants across HHIA scores, 
conventional and ultra high-frequency testing.  None of the tests are significant; therefore there is 



















 *. Correlation is significant at the 0.05 level (2-tailed) 
 
Table 8: Comparison of IV and non-IV participants across HHIA scores, conventional and ultra 
high-frequency testing.  None of the tests are significant, therefore there is no difference between 















 *. Correlation is significant at the 0.05 level (2-tailed) 
 
Table 9: Comparison of duration of tobramycin intake.  Group 1 represents 10 years or less 































 *. Correlation is significant at the 0.05 level (2-tailed) 
 
Table 10: Comparison of participants who use tobramycin for 10 years or fewer compared to 
baseline threshold ≤ 15 dB HL.  There is significant (p < .05) worse hearing in high-frequency 



















 *. Correlation is significant at the 0.05 level (2-tailed) 
 
Table 11: Comparison of participants who use tobramycin for more than 10 years compared to 
baseline hearing threshold ≤ 15 dB HL.  There is significant (p < .05) worse hearing at ultra 























Figure 1:  Graphical representation of an audiogram of hearing thresholds (dB HL) across 
conventional frequencies (Hz), one displaying the right ear and one for the left ear, as shown 
above.  Average hearing thresholds from all participants with CF per ear are defined from the red 

























Figure 2:  Graphical representation of an audiogram of hearing thresholds (dB HL) across ultra 
high-frequencies (Hz), one displaying the right ear and one for the left ear, as shown above.  
Average hearing thresholds from all participants with CF per ear are defined from the red line 

























Figure 3: The graphical relationship between the self-report HHIA scores and objective test of 

















Figure: 4: The relationship between the self-report HHIA scores and objective test of bone-

















Figure: 5: The relationship between the self-report HHIA scores and objective test of ultra high-


















Figure 6: Graphical representation of an audiogram of average hearing thresholds (dB HL) 
across conventional and ultra high-frequencies (Hz), one displaying the right ear and one for the 
left ear, as shown above.  A key is shown above representing the difference between those 
participants with CF taking tobramycin for 10 years or fewer and those taking tobramycin for 
















Appendix A:  Hearing Handicap Inventory for Adults (HHIA) – Original Version 
Granted permission from Dr. Craig Newman, Ph.D.   
Revised to use at WUSM Center for Advanced Medicine, Adult Audiology 
* = Designated items comprising of the HHIA-S – Screening Version  






S-1 Does a hearing problem cause you to use the phone less often than 
you would like? 
 
   
E-2* Does a hearing problem cause you to feel embarrassed when 
meeting new people? 
 
   
S-3 Does a hearing problem cause you to avoid groups of people? 
 
 
   
E-4 Does a hearing problem make you irritable? 
 
 
   
E-5* Does a hearing problem cause you to feel frustrated when talking to 
members of your family? 
 
   




   
E-7* Does a hearing problem cause you to feel frustrated when talking to 
coworkers, clients, or customer? 
 
   
E-8* Do you feel handicapped by a hearing problem? 
 
 
   
S-9 Does a hearing problem cause you difficulty when visiting friends, 
relatives, or neighbors? 
 
   
E-10 Does a hearing problem cause you to feel frustrated when talking to 
coworkers, client or customers? 
 
   




   
E-12 Does a hearing problem cause you to be nervous? 
 
 
   
S-13 
 
Does a hearing problem cause you to visit friends, relatives, or 
neighbors less often than you would like? 
 
   
E-14* Does a hearing problem cause you to have arguments with family 
members? 
 

















S-15* Does a hearing problem cause you difficulty when listening to TV or 
radio? 
 
   
S-16 Does a hearing problem cause you to go shopping less often than you 
would like? 
 
   
E-17 Does any problem or difficulty with your hearing upset you at all? 
 
 
   
E-18 Does a hearing problem cause you to want to be by yourself? 
 
 
   
S-19 Does a hearing problem cause you to talk to family members less 
often than you would like? 
 
   
E-20* Do you feel that any difficulty with your hearing limits or hampers 
your personal or social life? 
 
   
S-21* Does a hearing problem cause you difficulty when in a restaurant 
with relatives or friends? 
 
   
E-22 Does a hearing problem cause you to feel depressed? 
 
 
   
S-23 Does a hearing problem cause you to listen to TV or radio less often 
than you would like? 
 
   
E-24 Does a hearing problem cause you to feel uncomfortable when 
talking to friends? 
 
   
E-25 Does a hearing problem cause you to feel left out when you are with 
a group of people? 
 
   
